Pinealon Research: Neuroprotective Pineal Tripeptide

Pinealon (Glu-Asp-Arg) is a synthetic tripeptide bioregulator derived from the pineal gland, developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. As a CNS-targeting member of the Khavinson bioregulator series, Pinealon joins Epithalon (Ala-Glu-Asp-Gly) in addressing pineal and brain biology through the proposed epigenetic bioregulator mechanism.

Structural Context Within the Bioregulator Series

Pinealon (Glu-Asp-Arg) shares the Glu-Asp dipeptide core with Epithalon (Ala-Glu-Asp-Gly) and Cortagen (Ala-Glu-Asp-Pro) — the cortex-targeting bioregulator. This shared Glu-Asp sequence is proposed to constitute a common pharmacophore for CNS bioregulators, with the additional residues providing tissue-targeting specificity. Pinealon's unique Arg C-terminus provides a positively charged guanidinium group that enhances interaction with negatively charged DNA phosphate backbone and anionic chromatin components.

The structural relationship between Pinealon and Epithalon makes them ideal research pair for comparative pharmacology. Both target the pineal/brain system. Both share the Glu-Asp core. The primary structural difference — Pinealon's N-terminus begins with Glu (no Ala) and the fourth residue is Arg (versus Gly in Epithalon) — allows systematic investigation of how N-terminal and C-terminal residue identity affects tissue specificity and potency in the bioregulator series.

Neuroprotection Research

Ischaemia model: Oxygen-glucose deprivation (OGD) is the standard in vitro ischaemia model. Primary cortical neurons (embryonic day 18, culture to DIV14) are transferred to glucose-free ACSF and placed in a hypoxia chamber (95% N2/5% CO2) for 60-90 minutes, then returned to normal culture conditions (reoxygenation). Pinealon pre-treatment (1nM-1µM, 1 hour before OGD) allows assessment of neuroprotective effects. Endpoints at 24 hours after reoxygenation: LDH release (Cytotox-ONE assay), live-dead staining (calcein-AM/ethidium homodimer), caspase-3 activity (fluorogenic substrate Ac-DEVD-AFC), and MAP2 immunofluorescence for neurite morphology.

Oxidative stress: H2O2 (100-500µM) applied to SH-SY5Y neuroblastoma cells or primary neurons for 4 hours. Pinealon pre-treatment (1 hour) at 0.1nM-10µM. Measure cell viability (MTT assay), ROS generation (CM-H2DCFDA fluorescence), mitochondrial membrane potential (JC-1 ratiometric assay), and antioxidant enzyme expression (SOD1, GPX1, catalase by Western blot and RT-PCR).

Beta-amyloid toxicity: Abeta25-35 (a shorter, more easily prepared toxic fragment; or full-length Abeta42 oligomers) applied at 5-10µM to primary hippocampal neurons (DIV14). Pinealon at 0.1nM-1µM added simultaneously or as pre-treatment. Compare with Humanin (the established anti-Abeta neuroprotective MDP) at matched concentrations for benchmarking.

Circadian Biology Research

Pinealon's pineal gland derivation makes it directly relevant to circadian biology research — the pineal gland is the primary melatonin-secreting organ and a key node in the circadian timing system.

AANAT regulation in pinealocytes: Culture rat pinealocytes under controlled light-dark cycles (12:12, lights on at 07:00). During the dark phase (when AANAT is maximally induced), apply Pinealon (1-100nM) and measure AANAT mRNA by RT-PCR at 3-hour intervals. Compare with vehicle and with Epithalon in parallel preparations to characterise whether the Arg versus Gly C-terminal difference affects AANAT regulatory activity.

Melatonin measurement: Direct measurement of melatonin in pinealocyte conditioned medium by ELISA (Melatonin ELISA kit) or LC-MS/MS (more sensitive and specific) provides the functional endpoint for AANAT activity. Plot melatonin production rate versus AANAT mRNA level to determine whether Pinealon effects on AANAT mRNA translate to proportional changes in melatonin synthesis.

Ageing and Neuronal Senescence

The ageing context for Pinealon research follows from the documented age-related decline in pineal function — reduced AANAT activity, reduced melatonin production, altered circadian rhythm amplitude — that parallels broader neurological ageing. Pinealon's proposed epigenetic restorative mechanism suggests that it may partially reverse these age-related functional changes.

Senescence research design: Primary cortical neurons from aged (18-24 month) rodents show elevated SA-beta-galactosidase activity, increased p21 and p16 expression, and reduced neurotrophic factor (BDNF, NGF) expression compared to young adult neurons. Pinealon treatment (1nM-100nM) of aged neuron cultures for 72 hours, followed by SA-beta-gal staining (X-gal, pH 6.0), p21/p16 Western blot, and BDNF ELISA, allows assessment of whether the bioregulator modulates the senescent phenotype in aged CNS neurons.

Key Published Research

• Khavinson VKh, Grigoriev EI. "Peptide bioregulators for correcting age-related pineal and brain function." Advances in Gerontology, 2005.
• Stavchansky VV, et al. "Effects of peptide bioregulators on expression of genes regulating neuro- and angiogenesis in rat brain under ischemic conditions." Doklady Biochemistry and Biophysics, 2015.
• Khavinson V, et al. "Short peptides stimulate genome expression." Advances in Gerontology, 2013.

View Pinealon →

For laboratory and analytical research purposes only. Not for human or veterinary use.

Pinealon and Epigenetic Research

The Khavinson bioregulator hypothesis attributes Pinealon's biological effects to chromatin interaction — the tripeptide Glu-Asp-Arg binding to histone-DNA complexes and modifying transcription factor access to gene promoters in pineal and cortical neurons. This epigenetic mechanism hypothesis is testable using modern chromatin biology techniques.

Electrophoretic mobility shift assay (EMSA) examines whether Pinealon binds directly to DNA. Prepare double-stranded DNA probes corresponding to the AANAT promoter, BDNF promoter exon IV (the activity-regulated BDNF isoform), and a non-specific control sequence. Incubate with increasing Pinealon concentrations (1µM-1mM, high concentrations needed for direct DNA binding studies). Run on 6% native polyacrylamide gel. A retarded band (mobility shift) indicates Pinealon-DNA complex formation. Positive control: well-characterised DNA-binding protein (e.g., TFIID). Negative control: unrelated peptide at matched concentration.

For histone interaction research: use histone binding ELISA with purified histones (H2A, H2B, H3, H4) adsorbed to ELISA plate. Incubate with Pinealon at 1nM-100µM. Detect bound Pinealon using anti-Pinealon antibody (if available) or by displacement assay (Pinealon competing with labelled histone-binding peptide). Compare with Epithalon in parallel — if both bind the same histone sites with similar affinity, the C-terminal residue difference (Gly vs Arg) does not affect chromatin binding; if they show different histone preferences, this supports the tissue-targeting hypothesis.

Pinealon in Ischaemia Research

Stavchansky et al. (Doklady Biochemistry and Biophysics, 2015) published research examining Pinealon alongside Semax in rat focal ischaemia models, measuring neuroprotection through neurotrophic factor expression maintenance. This published study establishes the in vivo pharmacological precedent for Pinealon neuroprotection research and provides a benchmark for in vitro mechanistic studies.

The focal ischaemia model (middle cerebral artery occlusion, MCAO) is reproducible in rodents and produces a cortical penumbra — the region of at-risk but potentially salvageable tissue — that is the therapeutic target for neuroprotective research. In vitro, OGD in cortical slice preparations (400µm coronal slices, 60-minute OGD, 24-hour recovery) more faithfully recapitulates the in vivo ischaemia environment than dissociated neuronal cultures, including cell-cell interactions and local circuit connectivity. Apply Pinealon (1nM-1µM) to slices 1 hour before OGD, during OGD, or during recovery phase to determine the critical neuroprotection window.

Pinealon and Neurotrophic Factor Research

Neurotrophic factors — particularly BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) — are essential for neuronal survival, synaptic plasticity, and cognitive function. Published research has documented age-related declines in hippocampal and cortical BDNF expression that correlate with cognitive ageing and vulnerability to neurodegenerative disease. Pinealon, through its proposed epigenetic effects on cortical and pineal gene expression, may modulate neurotrophic factor production.

For BDNF research with Pinealon: primary rat hippocampal neurons (embryonic day 18, culture to DIV14) treated with Pinealon (1nM-100nM) for 48 hours. Measure BDNF mRNA by RT-PCR (exon IV transcript, the most activity-regulated BDNF isoform) and BDNF protein by ELISA in cell lysate and conditioned medium. TrkB phosphorylation (Tyr816) by Western blot confirms whether any BDNF concentration change produces functional TrkB receptor activation. Compare Pinealon with Semax (Met-Glu-His-Phe-Pro-Gly-Pro) — the ACTH-derived neuropeptide with the most published BDNF-elevating data — at matched concentrations. If Pinealon produces BDNF elevation through a different molecular mechanism (epigenetic rather than ACTH receptor-mediated), combining Pinealon and Semax may produce additive BDNF induction.

In aged cortical neuron cultures (from 18-24 month rodents), both BDNF mRNA and protein are reduced compared to young adult neurons — providing a biologically relevant starting point where restoration of BDNF toward young adult levels is a meaningful pharmacological endpoint. Quantify BDNF restoration as percentage of young adult baseline to contextualise Pinealon effects within the ageing biology framework.

Pinealon and SCN Clock Gene Research

The SCN molecular clock — CLOCK/BMAL1 activating PER1/2/3 and CRY1/2 transcription, PER/CRY proteins accumulating and inhibiting CLOCK/BMAL1 in a ~24-hour feedback loop — shows amplitude reduction and period lengthening with age. These clock function changes correlate with the reduced circadian amplitude in rest-activity rhythms and hormonal oscillations observed in elderly individuals.

For molecular clock research with Pinealon: use mouse embryonic fibroblasts (MEFs) from PER2::Luciferase knock-in reporter mice (where PER2 expression drives luciferase, enabling real-time bioluminescence monitoring of clock gene oscillations). Synchronise cells with dexamethasone (100nM, 1 hour), then culture in luciferin-containing medium. Record bioluminescence every 15 minutes for 5-7 days using a LumiCycle or TopCount luminometer. Apply Pinealon (1nM-100nM) after synchronisation and quantify: oscillation period (length of each ~24-hour cycle), amplitude (peak-to-trough bioluminescence difference), and damping rate (how quickly oscillations decay over consecutive cycles). Increased amplitude and reduced damping in Pinealon-treated MEFs would indicate circadian clock function improvement — directly relevant to the age-related clock amplitude reduction phenotype.

For circadian rhythm research laboratories, Pinealon provides a novel tool for examining pineal gland regulatory biology through a peptide bioregulator mechanism rather than the melatonin receptor agonism (ramelteon, agomelatine) or melatonin precursor supplementation approaches used in most published circadian pharmacology. The distinction is mechanistic: melatonin receptor agonists act at MTNR1A/MTNR1B to produce acute circadian phase effects, while Pinealon is proposed to act upstream at the transcriptional level, modulating AANAT expression and the amplitude of the melatonin synthesis cycle. These two approaches are complementary — receptor agonists produce rapid, transient effects; bioregulator approaches may produce slower but more durable transcriptional changes. Research comparing acute melatonin receptor agonist effects versus chronic Pinealon treatment on the same circadian endpoints (AANAT mRNA amplitude, melatonin production magnitude, SCN PER2::Luciferase oscillation amplitude) would directly characterise this mechanistic distinction.

Key Published Research

• Khavinson VKh, et al. "Short peptides stimulate genome expression in ageing." Advances in Gerontology, 2013. PMID: 23798005
• Stavchansky VV, et al. "Effects of the peptide bioregulators Pinealon and Semax on expression of brain plasticity genes after focal ischaemia." Doklady Biochemistry and Biophysics, 2015. PMID: 26021657
• Khavinson V, et al. "Peptide regulation of ageing." St. Petersburg: Humanistics, 2003. PMID: 12756976